• Category: Medical Devices
  • Investment Status: Advanced
  • Medical Field: Orthopedics
  • Patent Status: Hydrogel patent granted in USA, pending in EU – Injection device patent granted in EU, pending in USA
  • Development Status: Pre-clinical
  • Medical Center: Ha'sharon
  • Inventors: DR. Dror Robinson,Prof. Zvi Nevo, PhD,  Noah Ben Shalom, PhD

Osteoarthritis (OA) is one of the most frequent causes of physical disability in adults. The disease involves progressive deterioration of articular cartilage with some level of inflammation. OA presently has no cure to date.  One of the most accepted therapeutic solutions to delay the need for Total Knee Replacement is called Visco-supplementation and aims at supplementing the viscosity of the joint fluid, thereby lubricating the joint, cushioning the joint, and producing an analgesic effect. However, while they are a commercial success, these products have important limitations especially in terms of efficacy and lasting effect.

  • Developing its proprietary innovative Chitosan-Hyaluronate hybrid hydrogel
  1. Has demonstrated superior features in pre-clinical studies
  2. Seems better than current commercially available Hyaluronate based gels
  • For spine indication,  also developing innovative proprietary injection system
  1. Will allow a minimally invasive procedure to restore intervertebral disc height
  2. Will allow to securely injecting Chi2Gel hybrid hydrogel into the disc.
  • Prolonged intra-articular half-life w/o chemical modifications of Chitosan
  • Synergistic effects of both Chitosan polysaccharides + Hyaluronate in one product
  • Strong differentiation potential in competitive Hyaluronate market – superior pain reduction and preservation of cartilage in osteoarthritis animal model
  • Positive electric charge of chitosan allows coating of the cartilage defects
  • Potentially promoting repair activity of the cartilage.